Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Characterizing the molecular changes of Basal Cell Carcinoma during vismodegib treatment

ABSTRACT: Characterizing the molecular changes of Basal Cell Carcinoma during vismodegib treatment

PROVIDER: PRJNA480702 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR5831660.fastq.gz	Fastqsanger.gz
	SRR5831661.fastq.gz	Fastqsanger.gz
	SRR5831662.fastq.gz	Fastqsanger.gz
	SRR5831663.fastq.gz	Fastqsanger.gz
	SRR5831664.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 48

Similar Datasets

Characterizing the molecular changes of Basal Cell Carcinoma during vismodegib treatment

Project description:This SuperSeries is composed of the SubSeries listed below.

2018-08-08 | GSE116966 | GEO

A slow cycling Lgr5 tumour population mediates basal cell carcinoma relapse after therapy

Project description:We used microarray analysis to molecularly profile distinct tumour cell populations present in untreated and vismodegib-treated basal cell carcinomas.

2018-10-11 | GSE117458 | GEO

Genomic analysis of Smoothened inhibitor resistance in basal cell carcinoma

Project description:Smoothened inhibitors are currently being investigated for the treatment of several cancers. Vismodegib is approved for the treatment of locally advanced and metastatic basal cell carcinoma (BCC). The majority of BCC patients treated with vismodegib experience significant clinical benefit, however, a small number of patients develop resistance. Knowledge of resistance mechanisms can generate predictive biomarkers and is critical for the design of additional therapeutic strategies aimed at circumventing resistance. To investigate mechanisms of resistance to vismodegib in BCC we sequenced and profiled biopsies from patients who initially responded to treatment and subsequently progressed on drug. We find that resistance is associated with re-activation of the Hedgehog (Hh) pathway through diverse mechanisms, including concurrent copy number alterations in the downstream Hh pathway components SUFU and GLI2, as well as novel SMO mutations that reduce sensitivity to vismodegib. The latter fall into two classes: those that activate SMO and those that directly affect the vismodegib-binding pocket. Additionally, we observe evidence of clonal selection of SMO mutations and intra-tumor heterogeneity of resistance mechanisms, which implies diverse and combinatorial strategies are required to overcome resistance.

| EGAS00001000845 | EGA

A transcriptome-based molecular census of human basal cell carcinoma subtypes at single cell resolution

Project description:We report the single cell transcriptomes of 4 basal cell carcinoma subtypes and 2 peri-tumor skin samples.

2020-08-14 | GSE141526 | GEO

TEAD transcriptional inhibition in basal cell carcinoma

Project description:TEAD transcriptional inhibition in basal cell carcinoma

| PRJNA659502 | ENA

Transcription profiling of human ductal carcinoma in situ (DCIS) and invasive component (IDC) from 9 breast cancers to identify novel molecular markers characterizing the transition from DCIS to IDC.

Project description:This is a matched-pair analysis of ductal carcinoma in situ (DCIS) and invasive component (IDC) of nine breast ductal carcinoma to identify novel molecular markers characterizing the transition from DCIS to IDC for a better understanding of its molecular biology.

2007-10-02 | E-GEOD-3893 | biostudies-arrayexpress

Transcriptional changes in experimentally-induced basal to squamous cell carcinoma transition (BST) upon treatment with small molecule inhibitors [ASZ_RNAseq_inhibitor]

Project description:Basal cell carcinoma may undergo BST spontaneously or upon Hedgehog targeting therapy. We identified that either modulation of Ras/MAPK or TGFb signaling or c-FOS induction could drive BST. Enhanced EGFR signaling has been implicated during BST. Here, we analyze transcriptional profiles upon c-FOS induction when cells are treated with EGFR signaling inhibitors afatinib (5uM) and UO126 (10uM).

2021-10-20 | GSE166596 | GEO

Investigating transcriptional programs regulating invasion in basal cell carcinoma

Project description:Investigating transcriptional programs regulating invasion in basal cell carcinoma through scRNAseq analysis

2024-05-31 | GSE266665 | GEO

Transcriptional changes in experimentally-induced basal to squamous cell carcinoma transition (BST) [ASZ_cFOS_RNAseq]

Project description:Basal cell carcinoma may undergo BST spontaneously or upon Hedgehog targeting therapy. We identified that modulation of Ras/MAPK or TGFb signaling drive BST. Here, we induce Ras/MAPK and/or abrogate TGFb signaling to induce BST. Alternatively we drive c-FOS to induce BST. Here, we analyze transcriptional profiles upon c-FOS induction.

2021-10-05 | GSE166595 | GEO

MicroRNA signatures associated with basal cell carcinoma subtypes

Project description:MicroRNA signatures associated with basal cell carcinoma subtypes

| PRJNA1029545 | ENA